NASDAQ:HSIC - Henry Schein Stock Price, News, & Analysis

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Henry Schein's stock split before market open on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly minted shares were issued to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein declared that its board has initiated a stock repurchase program on Tuesday, September 19th 2017, which allows the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 6.3% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's leadership believes its shares are undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) issued its quarterly earnings data on Tuesday, November, 6th. The company reported $1.03 EPS for the quarter, beating the Zacks' consensus estimate of $1.01 by $0.02. The business earned $3.28 billion during the quarter, compared to analysts' expectations of $3.37 billion. Henry Schein had a return on equity of 20.40% and a net margin of 3.00%. The business's revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.87 earnings per share. View Henry Schein's Earnings History.

Henry Schein is scheduled to release their next quarterly earnings announcement on Tuesday, February 19th 2019. View Earnings Estimates for Henry Schein.

Henry Schein updated its FY18 earnings guidance on Tuesday, November, 6th. The company provided EPS guidance of $4.06-4.14 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.12.

18 Wall Street analysts have issued 1-year target prices for Henry Schein's shares. Their predictions range from $66.00 to $102.00. On average, they expect Henry Schein's stock price to reach $83.5625 in the next twelve months. This suggests that the stock has a possible downside of 1.2%. View Analyst Price Targets for Henry Schein.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 2 sell ratings, 8 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Henry Schein.

Media stories about HSIC stock have trended positive on Thursday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Henry Schein earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future.

Some companies that are related to Henry Schein include Allergan (AGN), Boston Scientific (BSX), Celgene (CELG), HCA Healthcare (HCA), Illumina (ILMN), Zoetis (ZTS), Humana (HUM), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Baxter International (BAX), Edwards Lifesciences (EW), Actelion (ALIOF), ASTELLAS PHARMA/ADR (ALPMY), Centene (CNC) and Alexion Pharmaceuticals (ALXN).

Henry Schein's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Longview Partners Guernsey LTD (8.92%), BlackRock Inc. (6.94%), FMR LLC (5.69%), Select Equity Group L.P. (4.08%), Brown Brothers Harriman & Co. (3.40%) and Alecta Pensionsforsakring Omsesidigt (3.24%). Company insiders that own Henry Schein stock include Barry J Alperin, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Mackenzie Financial Corp, Deutsche Bank AG, Alecta Pensionsforsakring Omsesidigt, Select Equity Group L.P., Brown Brothers Harriman & Co., Schroder Investment Management Group and JPMorgan Chase & Co.. Company insiders that have sold Henry Schein company stock in the last year include Barry J Alperin, Mark E Mlotek and Paul Brons. View Insider Buying and Selling for Henry Schein.

HSIC stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Atlanta Capital Management Co. L L C, Morgan Stanley, AXA, American Century Companies Inc., WINTON GROUP Ltd, Ancora Advisors LLC and First Trust Advisors LP. View Insider Buying and Selling for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $84.56.

Henry Schein has a market capitalization of $13.15 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

The official website for Henry Schein is http://www.henryschein.com.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]